Year: 2015
Type: review
Abstract: Malignant cells routinely violate cellular checkpoints that should initiate cell death in normal cells by triggering pro-apoptotic members of the BCL-2 family of proteins. To escape such death inducing signals, cancer cells often select for upregulation of anti-apoptotic BCL-2 family members including BCL-2, BCL-XL , BFL-1, BCL-W and MCL-1. These family members prevent death by sequestering pro-apoptotic molecules. To counter this resistance mechanism, small molecule inhibitors of anti-apoptotic BCL-2 family members have been under development. These molecules have shown promise in pre-clinical and clinical testing to overcome apoptotic resistance, prompting cancer cells to undergo apoptosis. Alternatively, other strategies have taken advantage of the normal regulatory machinery controlling anti-apoptotic molecules and have used inhibitors of signaling pathways to down-modulate the expression of anti-apoptotic molecules, thus tilting the balance in cancer cells to cell death. This review explores recent developments and strategies aimed at antagonizing anti-apoptotic BCL-2 family member action to promote the induction of cell death in cancer therapy.
Source: FEBS Journal
DOI: 10.1111/febs.13472
Author: Joseph T. Opferman
Institution: St. Jude Children's Research Hospital
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
Awards: Regulation of Anti-Apoptotic MCL-1 in B-lineage Acute Lymphoblastic Leukemi, Pathway Specific Combinational Therapy in Poor Prognosis B-Lineage Acute Lymphoblastic Leukemia, Regulation of Cell Death and Mitochondrial Physiology by Anti-Apoptotic MCL-1, Regulation of Cardiac Death and Energy Metabolism by MCL-1, Cancer Center Support Grant (CCSG)
OpenAlex ID: W2142098498
